TUHURA BIOSCIENCES INC (HURA) Fundamental Analysis & Valuation
NASDAQ:HURA • US8989201038
Current stock price
1.73 USD
-0.08 (-4.42%)
At close:
1.7089 USD
-0.02 (-1.22%)
After Hours:
This HURA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. HURA Profitability Analysis
1.1 Basic Checks
- HURA had negative earnings in the past year.
- In the past year HURA has reported a negative cash flow from operations.
- In the past 5 years HURA always reported negative net income.
- In the past 5 years HURA always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -170.33%, HURA is doing worse than 85.69% of the companies in the same industry.
- HURA's Return On Equity of -260.88% is on the low side compared to the rest of the industry. HURA is outperformed by 71.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -170.33% | ||
| ROE | -260.88% | ||
| ROIC | N/A |
ROA(3y)-224%
ROA(5y)-257.81%
ROE(3y)-832.26%
ROE(5y)-1280.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- HURA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. HURA Health Analysis
2.1 Basic Checks
- Compared to 1 year ago, HURA has less shares outstanding
- HURA has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for HURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- HURA has an Altman-Z score of -5.20. This is a bad value and indicates that HURA is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -5.20, HURA is not doing good in the industry: 62.86% of the companies in the same industry are doing better.
- HURA has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
- HURA has a Debt to Equity ratio (0.03) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.2 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- HURA has a Current Ratio of 0.40. This is a bad value and indicates that HURA is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Current ratio value of 0.40, HURA is not doing good in the industry: 91.30% of the companies in the same industry are doing better.
- A Quick Ratio of 0.40 indicates that HURA may have some problems paying its short term obligations.
- The Quick ratio of HURA (0.40) is worse than 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.4 | ||
| Quick Ratio | 0.4 |
3. HURA Growth Analysis
3.1 Past
- HURA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.62%, which is quite impressive.
EPS 1Y (TTM)65.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- HURA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.17% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-36.96%
EPS Next 2Y-4.26%
EPS Next 3Y-8.03%
EPS Next 5Y32.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. HURA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for HURA. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HURA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- HURA's earnings are expected to decrease with -8.03% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.26%
EPS Next 3Y-8.03%
5. HURA Dividend Analysis
5.1 Amount
- HURA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
HURA Fundamentals: All Metrics, Ratios and Statistics
1.73
-0.08 (-4.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners10.73%
Inst Owner Change3.84%
Ins Owners25.37%
Ins Owner ChangeN/A
Market Cap105.05M
Revenue(TTM)N/A
Net Income(TTM)-43.77M
Analysts82.22
Price Target9.18 (430.64%)
Short Float %15.69%
Short Ratio3.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)-52.55%
DP-0.01%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-23.75%
Min EPS beat(2)-62.53%
Max EPS beat(2)15.03%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.7%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.26 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.6
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0
BVpS0.28
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -170.33% | ||
| ROE | -260.88% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-224%
ROA(5y)-257.81%
ROE(3y)-832.26%
ROE(5y)-1280.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 58.02% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.4 | ||
| Quick Ratio | 0.4 | ||
| Altman-Z | -5.2 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)139.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.78%
EPS Next Y-36.96%
EPS Next 2Y-4.26%
EPS Next 3Y-8.03%
EPS Next 5Y32.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-407.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-906.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-903.22%
OCF growth 3YN/A
OCF growth 5YN/A
TUHURA BIOSCIENCES INC / HURA Fundamental Analysis FAQ
What is the fundamental rating for HURA stock?
ChartMill assigns a fundamental rating of 1 / 10 to HURA.
What is the valuation status for HURA stock?
ChartMill assigns a valuation rating of 0 / 10 to TUHURA BIOSCIENCES INC (HURA). This can be considered as Overvalued.
Can you provide the profitability details for TUHURA BIOSCIENCES INC?
TUHURA BIOSCIENCES INC (HURA) has a profitability rating of 0 / 10.
How sustainable is the dividend of TUHURA BIOSCIENCES INC (HURA) stock?
The dividend rating of TUHURA BIOSCIENCES INC (HURA) is 0 / 10 and the dividend payout ratio is -0.01%.